Functional Gut Clinic Launches Specialized Clinical Trials Division to Accelerate Digestive Health Research
Key Insights
The Functional Gut Clinic (search) has launched the UK's first boutique clinical research organization dedicated exclusively to digestive health, addressing fragmented and under-resourced gastrointestinal research.
The division leverages the UK's largest volunteer bank for digestive health research with 5,000 opted-in participants and demonstrated fast-track recruitment capabilities completing studies from ethics approval to full enrollment in under six months.
FGC's specialized approach combines unmatched diagnostic expertise delivering over 12,000 GI physiology tests annually with precision screening capabilities, setting it apart from generalist contract research organizations.
The Functional Gut Clinic (search) (FGC) has established the UK's first boutique clinical research organization dedicated exclusively to digestive health, launching a specialized Clinical Trials Division that aims to address the historically fragmented and under-resourced landscape of gastrointestinal research.
The new division positions FGC as an end-to-end clinical research provider focused specifically on digestive health conditions affecting millions of people in the UK. Unlike generalist contract research organizations, FGC's specialized approach targets next-generation therapies for conditions including irritable bowel syndrome (search) (IBS), small intestinal bacterial overgrowth (search) (SIBO), reflux (search), motility disorders (search), and functional gastrointestinal diseases (search).
Competitive Advantages in GI Research
FGC enters the clinical trials market with three distinct advantages that differentiate it from traditional CROs. The organization maintains the UK's largest volunteer bank for digestive health research, comprising 5,000 opted-in individuals living with digestive health conditions. This extensive patient database enables rapid recruitment capabilities, demonstrated by the company's ability to complete studies from ethics approval to full enrollment in under six months.
The third competitive advantage lies in FGC's diagnostic expertise, delivering over 12,000 GI physiology tests annually through the only independent UKAS-accredited GI physiology service in the country. This diagnostic capability allows for rapid participant screening with clinical precision that significantly streamlines study startup processes.
"Digestive health research has historically been slowed by two challenges: finding the right patients and understanding their physiology in enough depth," explains Professor Anthony Hobson, Founder of the Functional Gut Clinic (search). "At the Functional Gut Clinic, we have built the UK's largest bank of opted-in volunteers with digestive conditions, and we combine this with unparalleled diagnostic capability."
Proven Track Record with EnteroBiotix Partnership
The Clinical Trials Division launch follows the successful completion of a phase 2a IBS study for EnteroBiotix (search), which enrolled 122 participants. FGC played a central role in the trial, supporting participant recruitment, clinical assessment, and ongoing care through its research volunteer database, enabling the study to progress from ethics approval to full enrollment in under six months.
"The Functional Gut Clinic (search) played a pivotal role in enabling the successful delivery of our phase 2a trial," states Dr. James McIlroy, founder and CEO of EnteroBiotix (search). "Their ability to deliver a compliant study within agreed timelines, assess patients with precision and provide high quality clinical oversight made a meaningful difference to the study."
The strength of this collaboration is reflected in Professor Hobson's presentation of the data at Digestive Disease Week 2025 as a late-breaking oral presentation, with EnteroBiotix (search) expressing interest in expanding their partnership for future development phases.
Comprehensive Service Portfolio
FGC has already delivered research programs for leading global companies including ADM Protexin (search) (Bio-Kult (search)), Reckitt Benckiser (Gaviscon), Medtronic, and EnteroBiotix (search), supporting studies across probiotics, over-the-counter medicines, medical devices, and microbiome therapeutics.
The boutique specialist model offers several key capabilities tailored to digestive health research complexities. These include deep GI expertise across physiology, motility, reflux (search), microbiome science, and functional disorders, combined with precision screening using advanced diagnostic testing for high-quality participant selection.
The division provides agile, flexible trial delivery across multiple established UK sites, with end-to-end support spanning study design and ethics preparation to data analysis and publication. Access to a vast and highly engaged patient community enables rapid recruitment and high retention rates.
Sam Treadway, Chief Scientific Officer at the Functional Gut Clinic (search), emphasizes the integrated approach: "By integrating our diagnostic expertise with our research infrastructure and a large, engaged volunteer community, we can deliver trials that move quickly without compromising scientific rigour. We provide sponsors with a specialist partner who understands the nuances of GI disease far better than a general research organisation."
Strategic Investment and Expansion
The Clinical Trials Division launch is supported by a £5.75 million investment from Foresight Group (search), announced in 2025. This investment is enabling expansion of FGC's national footprint, growth of its clinical research team, and strengthening of trial delivery infrastructure.
FGC currently operates three permanent clinics in Manchester, Cambridge, and London, alongside several collaborative clinics across the UK. The organization, founded in 2014 by Professor Anthony Hobson, maintains its position as the UK's leading provider of specialist gastrointestinal diagnostics, delivering more than 12,000 tests annually while holding the distinction of being the only independent GI physiology service in the UK with UKAS accreditation.